The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Mumbai

Trends Update — Shifting IP Constituencies: AstraZeneca’s R&D Investment in India’s Jubilant

world_map_2002One of our trends in 2009 series is following the increasing innovative activity in India and China, which has the potential to reshape WTO debates around IP protection.

Yesterday, FierceBiotech picked up a Reuters report that AstraZeneca will be funding five years’ work in neuroscience R&D at India’s Jubilant Organosys.  Jubilant was… well … very happy about the deal, which could lead to up to $200 million in milestone payments.  Jubilant also works with Eli Lilly on drug discovery and partnered drug development.  Interestingly, the article juxtaposes Jubilant’s R&D deal with its Monday FDA approval for a generic product.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 130 other followers